A

ROC of baseline IL-2 — AUC= 0.5516, *P*-value= 0.7046
ROC of baseline IL-7 — AUC= 0.6230, *P*-value= 0.3660
ROC of baseline IL-18 — AUC= 0.6429, *P*-value= 0.2938
ROC of baseline IL-1β — AUC= 0.6032, *P*-value= 0.4483
ROC of baseline IL-21 — AUC= 0.5397, *P*-value= 0.7706
ROC of baseline IL-22 — AUC= 0.5952, *P*-value= 0.4840
ROC of baseline IL-27 — AUC= 0.5159, *P*-value= 0.9071
ROC of baseline IL-4 — AUC= 0.5040, *P*-value= 0.9767

B

ROC of baseline BDNF — AUC= 0.5794, *P*-value= 0.5598
ROC of baseline PDGF-BB — AUC= 0.6984, *P*-value= 0.1448

C

ROC of baseline IL-6 — AUC= 0.5556, *P*-value= 0.6831
ROC of baseline IP-10 — AUC= 0.6905, *P*-value= 0.1616
ROC of baseline IL-1RA — AUC= 0.5159, *P*-value= 0.9071

All axes: Sensitivity% (y) vs 100% - Specificity% (x)

Supplemental Figure 5. Prognostic value of immune mediators at baseline to identify responders from responders from non-responders from patients treated with Remdesivir. Prognostic analyses were performed with Receiver Operating Characteristic (ROC) Wilson-Brown analysis at 95 % Confidence Interval. Baseline levels of **(A)** T-cell associated mediators, **(B)** growth factors and **(C)** inflammatory-associated mediators were measured in plasma samples of COVID-19 patients before RDV treatment. All Patients (n=27) were receiving supplemental oxygen and not intubated prior to treatment. Patients were categorized based on their eventual disease progression to requiring intubation (Non-responders (patients), median 7 days post-illness onset (PIO), n=6), or not (Responders (controls), median 9 days PIO, n=21). Patient samples with concentration out of measurement range are presented as the value of Limit of Quantification (LOQ) for the analysis.

Supplementary Figure 5 , Chan et al., 2021